Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
9.90
-0.16 (-1.59%)
Aug 14, 2025, 11:55 AM - Market open
Arcus Biosciences Employees
Arcus Biosciences had 627 employees as of December 31, 2024. The number of employees increased by 50 or 8.67% compared to the previous year.
Employees
627
Change (1Y)
50
Growth (1Y)
8.67%
Revenue / Employee
$417,863
Profits / Employee
-$475,279
Market Cap
1.05B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 627 | 50 | 8.67% |
| Dec 31, 2023 | 577 | 77 | 15.40% |
| Dec 31, 2022 | 500 | 134 | 36.61% |
| Dec 31, 2021 | 366 | 130 | 55.08% |
| Dec 31, 2020 | 236 | 97 | 69.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RCUS News
- 4 days ago - Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months - Seeking Alpha
- 7 days ago - Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 20 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 5 weeks ago - Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer - Business Wire
- 2 months ago - Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response - Business Wire
- 3 months ago - Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 4 months ago - Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting - Business Wire